The Q1 beat is a positive reversal from FY 2025's 13% revenue decline, but ~37% of the net income increase came from a non-recurring settlement. Watch the Q2 10-Q for organic operating momentum without the settlement tailwind. The resumption of ASI's normal purchasing is the key sustainable catalyst.
Price Chart
Executive Summary
United-Guardian reported Q1 2026 net sales of $2.87M, up 15.8% YoY from $2.48M, and net income of $818.9K ($0.18/share) vs $560.9K ($0.12/share) in Q1 2025. The beat was driven by a 24% increase in pharmaceutical sales (Renacidin) and a 21% increase in cosmetic ingredients, plus a one-time $303K settlement from a contract manufacturer. This reverses the FY 2025 decline and signals a demand recovery, but the settlement income is non-recurring.
Key Financial Metrics
Key Facts
- Q1 2026 net sales $2,872,222 vs $2,481,127 YoY (+15.8%)
- Q1 2026 net income $818,902 ($0.18/diluted share) vs $560,895 ($0.12) YoY (+46%)
- Pharmaceutical sales rose 24% driven by Renacidin demand
- Cosmetic ingredient sales rose 21% as distributor ASI resumed normal purchasing after working off excess inventory
- Settlement income of $303,133 from contract manufacturer for 2023 facility shutdown — non-recurring
- Operating income $642,449 vs $610,922 YoY (+5.2%) — growth was primarily from settlement income, not operations
- Weighted average shares unchanged at 4,594,319
Financial Impact
Revenue +$391K (+15.8%), Net income +$258K (+46%) YoY; $303K of the increase is from a one-time settlement
Risk Factors
- Settlement income of $303K is non-recurring — Q2 will face a tougher comp without it
- FY 2025 revenue declined 13% — one quarter does not confirm a sustained recovery
- Heavy reliance on single distributor (ASI) for cosmetic ingredients — concentration risk
- Micro-cap ($32M market cap) with low liquidity — price moves may be exaggerated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003193 |
| Document: f8k_050826.htm | 0001171843-26-003193 |
| Document: 0001171843-26-003193-index-headers.html | 0001171843-26-003193 |
| Document: 0001171843-26-003193-index.html | 0001171843-26-003193 |
| Document: 0001171843-26-003193.txt | 0001171843-26-003193 |
| 8-K Data (Synthetic) | 0001171843-26-003193 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 7, 2026 11w ago | Press Release | $7.29 | awaiting T+60 | — | $6.70 (−8.09%) |
Jul 16, 2026 14w ago | 8-K | $7.50 $7.00 | ▼ −6.67% | ▼ −10.38% | $6.70 (−10.67%) |
May 8, 2026 24w ago | 8-K | $6.87 $7.10 | ▲ +3.35% | ▼ −1.49% | $6.70 (−2.47%) |
May 8, 2026 24w ago | Press Release | $6.87 $7.10 | ▲ +3.35% | ▼ −1.49% | $6.70 (−2.47%) |
Mar 27, 2026 30w ago | Press Release | $6.56 $7.11 | ▼ −8.38% | ▲ +7.68% | $6.70 (−2.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers